The agency’s acting head said a review should look into whether any interactions between agency staff and the drug developer, Biogen, broke F.D.A. rules.
from NYT > Health https://ift.tt/3yLVoCx
Subscribe to:
Post Comments (Atom)
Rose
0 comments:
Post a Comment